spacer
home > epc > summer 2002 > global edc adoption
PUBLICATIONS
European Pharmaceutical Contractor

Global EDC Adoption

Internet electronic data capture (EDC) is now established as an effective way of conducting clinical trials. Faster access to cleaner data, a more streamlined and less batch-based process and faster database lock are driving real benefits for trial sponsors, leading to a growing acceptance that EDC can be a better way of running studies.

With regions such as South America and Asia Pacific rapidly developing as areas for clinical trials based on the growing importance of these markets to pharma companies, and the adoption of international standards for conducting clinical research, are EDC studies a realistic option for global studies? In fact, online Internet EDC actually facilitates running studies across a number of geographically dispersed countries.

The unique capability to remotely access and centrally manage data as it rapidly accumulates from sites around the world removes the delays and costs inherent in the traditional labour-intensive paper shipping processes. As Internet use spreads rapidly throughout the world, the barriers to deploying EDC are quickly disappearing, making this an increasingly attractive approach for sponsors. There are now many examples of successful EDC trials running beyond the traditional areas of the US and Europe, including sites in Eastern Europe, Africa, Asia Pacific and China.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Mark Wren, Director of eService and Support, and Martin Young, Professional Services Director for Phase Forward

Mark Wren brings to Phase Forward over 15 years' experience of successfully implementing technology to the drug development process from both a sponsor and a vendor perspective. Prior to joining Phase Forward, Mark was Director of Clinical Trial Services at Dendrite International where he successfully implemented e-clinical trials systems for many of the large pharmaceutical companies. He has also held managerial positions at the Celltech Group and British Biotech.

Martin Young is Professional Services Director for Phase Forward, responsible for international consulting services and major technology transfer clients. Since establishing Phase Forward's international operations in 1999, Martin has been involved in building the international business and, following the Clinsoft acquisition in 2001, integrating both companies' operations outside North America. Over the past 18 years, Martin has undertaken a number of commercial, IT and re-engineering roles within the IT and pharmaceutical industries. Prior to joining Phase Forward, he worked for Glaxo Wellcome, leading internal and external ventures focused on improving the development process. Martin has a degree in Engineering Science and an Executive MBA.

spacer
Mark Wren
spacer
spacer
spacer
Martin Young
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Dynascan Discusses Company Advancements With Packaging Today Magazine

Dynascan’s Marketing Manager (MM) recently met up with Europe’s leading packaging magazine, Packaging Today. During the interview many topics were covered, and you can read the full article here, but below are a few highlights and brief summary of what was discussed…
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement